Science Explorer Back to mapMap
Discussion
Topic · Neurology

Neuroblastoma Research and Treatments

Neuroblastoma Research and Treatments is a research topic within Neurology. Science Explorer counts 36k research works in it since 1950. 10.4% of them reached the world's top 10% most cited for their field and year.

This cluster of papers represents a comprehensive exploration of neuroblastoma, covering topics such as genetic mutations (including ALK and MYCN), risk classification, staging systems, immunotherapy, and genomic analysis. The research also delves into therapy strategies and prognosis for patients with neuroblastoma.

  • Neuroblastoma
  • ALK
  • Genomic
  • MYCN
  • Therapy
  • Risk Classification
  • Immunotherapy
  • Genetic Mutations
  • Staging System
  • Prognosis
Research works
36k
fractional, since 1950
In the world top 10%
3.8k
per year above
Top-10% rate
10.4%
share of its works in the world top 10%
Growth, 2018-21 → 2022-25
+2%
the tick is no change
Largest producer
United States
39% of the 10 largest, 2022-now
Neuroblastoma Research and Treatments

This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.

Which countries lead Neuroblastoma Research and Treatments research?

By volume, the United States and China publish the most (1.8k and 807 works in 2022-now).

By volume, 2022-now

  1. 1 United States 1.8k works
  2. 2 China 807 works
  3. 3 India 360 works
  4. 4 Italy 305 works
  5. 5 Germany 293 works
  6. 6 Japan 292 works
  7. 7 United Kingdom 196 works
  8. 8 France 172 works
  9. 9 Spain 146 works
  10. 10 Canada 139 works

How concentrated that is

The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.

United States: 39.3%China: 18.1%India: 8.1%Italy: 6.8%6 others listed: 27.8%39%largest
United States1,755 · 39.3%China807 · 18.1%India360 · 8.1%Italy305 · 6.8%6 others listed1,239 · 27.8%

Shares of the rows listed above, not of the whole node.

Which institutions lead Neuroblastoma Research and Treatments research?

By volume in 2022-now, Harvard University publishes the most Neuroblastoma Research and Treatments research, followed by Capital Medical University and National Institutes of Health.

Who are the leading researchers in Neuroblastoma Research and Treatments?

The most-cited researchers publishing on Neuroblastoma Research and Treatments include Guido Kroemer, Bert Vogelstein and Gad A. Getz.

  1. 1 Guido Kroemer France 386k citations
  2. 2 Bert Vogelstein United States 373k citations
  3. 3 Gad A. Getz United States 364k citations
  4. 4 Elaine R. Mardis United States 346k citations
  5. 5 Hermann Brenner Germany 343k citations
  6. 6 Jun Wang China 340k citations
  7. 7 Robert A. Weinberg United States 301k citations
  8. 8 Richard A. Gibbs United States 292k citations
  9. 9 John Q. Trojanowski United States 286k citations
  10. 10 Todd R. Golub United States 283k citations

Ranked by citations received across their whole record, among researchers with at least three works on this topic.

What are the most cited papers in Neuroblastoma Research and Treatments?

The most cited paper in Neuroblastoma Research and Treatments is "The 2021 WHO Classification of Tumors of the Central Nervous System: a summary" (David N. Louis, Arie Perry, Pieter Wesseling et al., 2021), with 12,579 citations. Next come "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene" (11,844) and "IDH1 and IDH2 Mutations in Gliomas" (6,002).

Most cited papers
#PaperReleasedCitations
1 The 2021 WHO Classification of Tumors of the Central Nervous System: a summary David N. Louis, Arie Perry, Pieter Wesseling et al. · Neuro-Oncology Open access 3 May 2021 12,579
2 Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene Dennis J. Slamon, Gary M. Clark, Steven Wong et al. · Science 9 Jan 1987 11,844
3 IDH1 and IDH2 Mutations in Gliomas Hai Yan, Donald Williams Parsons, Genglin Jin et al. · New England Journal of Medicine Open access 18 Feb 2009 6,002
4 The 2007 WHO Classification of Tumours of the Central Nervous System David N. Louis, Hiroko Ohgaki, Otmar D. Wiestler et al. · Acta Neuropathologica Open access 5 Jul 2007 4,570
5 One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States James C. Yao, Manal M. Hassan, Alexandria T. Phan et al. · Journal of Clinical Oncology 18 Jun 2008 4,565
All 100 most cited papers, with filters and sorting

Where is Neuroblastoma Research and Treatments research done?

The largest centres of Neuroblastoma Research and Treatments research in 2022-now are Beijing (China), New York (United States), Shanghai (China) and Moscow (Russia). Among places with at least 20 works in it, it is an unusually large share of all research in Memphis, Heidelberg and Genoa.

Largest cities, 2022-now

  1. 1 BeijingChina 135 works
  2. 2 New YorkUnited States 100 works
  3. 3 ShanghaiChina 91 works
  4. 4 MoscowRussia 78 works
  5. 5 BostonUnited States 77 works
  6. 6 HoustonUnited States 74 works
  7. 7 PhiladelphiaUnited States 73 works
  8. 8 LondonUnited Kingdom 72 works
  9. 9 ParisFrance 66 works
  10. 10 RomeItaly 66 works

Where it is the local speciality

  1. MemphisUS · 47.0 works16×
  2. HeidelbergDE · 51.3 works8.5×
  3. GenoaIT · 24.1 works7.2×
  4. BethesdaUS · 49.6 works7.0×
← less than its size predicts1×more →

Location quotient: how much more of its research is in Neuroblastoma Research and Treatments than the world average.

See Neuroblastoma Research and Treatments on the map

Where is the best place to study Neuroblastoma Research and Treatments?

Among universities, judged by research, Harvard University, Karolinska Institutet and Lund University score highest, combining citation excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.

0%20%40%mean 20.7%fractional works in this field (log) →share of work in the world top 10% →Lund UniversityKarolinska InstitutetHarvard UniversityHeidelberg University
above the meannear itbelow it

One dot per university in the first ten of the table below, at the default weights. The upper left is the interesting corner: small places doing unusually strong work.

Citation excellenceshare of its work in the world top 10%, 2022-now and all time averaged
40%
Specialisationhow much of its work is in this field, counted up to 10× the world share
10%
Sizeits output in this field, on a log scale
30%
Growthoutput growth, counted from -20% to +20%
10%
Internationalshare of its work with a co-author abroad
10%
Each slider sets a weight; the share it gets of the score is beside it.
#UniversityScoreTop 10%SpecialisationWorksGrowth
1Harvard UniversityUnited States 79.422.5%4.6×76 -7.4%
2Karolinska InstitutetSweden 72.430.2%5.6×16 +0.9%
3Lund UniversitySweden 67.731.6%3.9×12 +71.3%
4Heidelberg UniversityGermany 66.514.5%8.3×33 +12.0%
5University of TorontoCanada 64.611.1%4.4×46 +16.3%
6Utrecht UniversityNetherlands 64.224.6%3.9×15 +39.4%
7Capital Medical UniversityChina 61.913.0%10.5×58 +47.7%
8University of PennsylvaniaUnited States 59.022.5%4.7×26 -16.9%
9University of Southern CaliforniaUnited States 55.517.8%5.6×24 -13.1%
10University of California, San FranciscoUnited States 55.219.2%5.0×19 -35.7%

Universities only. The score blends citation excellence (40%), size (30%), specialisation (10%), growth (10%), international reach (10%), 2022-now; growth compares 2018-21 with 2022-25 and counts up to +20%, since a jump from a small base is mostly noise.

Every institution in Neuroblastoma Research and Treatments, country by country

Is Neuroblastoma Research and Treatments research growing?

Output in 2022-2025 was 2% higher than in 2018-2021, peaking in 2022. The fastest-growing topics are Neuroblastoma Research and Treatments.

still counting19801990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is Neuroblastoma Research and Treatments as a percentage of every work published that year, 0.026% in 2024.

still counting0.025%0.050%0.075%Neuroblastoma Research and Treatments0.024% in 202519801990200020102020

Fractional works of Neuroblastoma Research and Treatments over all fractional works that year. How the balance of science has shifted.

How much of it reaches the world top 10%

Year by year.

still counting5%10%15%Neuroblastoma Research and Treatments10.4% in 2025200020102020

Of each year's works in it, the share that reached the world's 10% most cited for their field and year. A field is the world for its own topics, so there is no other line to hold it against.

Which topics inside it are moving

Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.

Discussion

Ask a question or share a note about Neuroblastoma Research and Treatments. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.